Literature DB >> 4147052

Spectrophotofluorometric and gas-liquid chromatographic methods for the estimation of mexiletine (Kö 1173) in plasma and urine.

J G Kelly, J Nimmo, R Rae, R G Shanks, L F Prescott.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4147052     DOI: 10.1111/j.2042-7158.1973.tb09155.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


× No keyword cloud information.
  9 in total

1.  The renal excretion of mexiletine (Kö 1173) under controlled conditions of urine pH.

Authors:  M A Kiddie; C M Kaye
Journal:  Br J Clin Pharmacol       Date:  1974-02       Impact factor: 4.335

2.  A rapid method for the determination of plasma mexiletine levels by gas chromatography.

Authors:  I D Bradbrook; C James; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

Review 4.  Mexiletine: a review of its pharmacological properties and therapeutic efficacy in arrhythmias.

Authors:  C Y Chew; J Collett; B N Singh
Journal:  Drugs       Date:  1979-03       Impact factor: 9.546

5.  Population pharmacokinetic parameters in patients treated with oral mexiletine.

Authors:  S Vozeh; G Katz; V Steiner; F Follath
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  The clinical pharmacology of mexiletine.

Authors:  N P Campbell; J G Kelly; A A Adgey; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

7.  Mexiletine disposition: individual variation in response to urine acidification and alkalinisation.

Authors:  B G Mitchell; J A Clements; A Pottage; L F Prescott
Journal:  Br J Clin Pharmacol       Date:  1983-09       Impact factor: 4.335

8.  Plasma mexiletine concentrations following combined oral and intramuscular administration.

Authors:  I D Bradbrook; P Feldschreiber; P J Morrison; H J Rogers; R G Spector
Journal:  Eur J Clin Pharmacol       Date:  1981-03       Impact factor: 2.953

9.  Treatment of recurrent sustained ventricular tachycardia with mexiletine and disopyramide. Control by programmed ventricular stimulation.

Authors:  M Manz; G Steinbeck; J Nitsch; B Lüderitz
Journal:  Br Heart J       Date:  1983-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.